Today Exact Sciences released earnings for the third quarter of 2017. Results exceeded our expectations with revenue of $72.6 million, up 26% from the second quarter, and 161,000 completed Cologuard tests, up 19% from the second quarter.
Quarterly test volume grew 136 percent to 161,000 completed tests
- Revenue guidance raised to $254-257 million for full-year 2017 from $230-240 million
- Guidance for Cologuard tests to be completed during 2017 increased to 568,000-572,000 tests from at least 550,000
- More than 10,000 additional providers ordered Cologuard for the first time during the third quarter
MADISON, Wis., Oct. 30, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $72.6 million and completed approximately 161,000 Cologuard tests during the quarter ended Sept. 30, 2017. Third-quarter 2017 revenue and completed Cologuard test volume grew 158 percent and 136 percent, respectively, from the same period of 2016.
MADISON, Wis., Oct. 18, 2017 /PRNewswire/ -- Exact Sciences, the manufacturer of Cologuard, announced today the four Grand Prize winners of the Green Bay Packers-Cologuard Colon Cancer Awareness Campaign. Each receives two bowl tickets to the Packers game at Lambeau Field on Sunday, October 22. Winning names were drawn from more than 1,300 entries.
The ticket winners are: Nicholas Pierson (Oshkosh, Wis.); Nathan Plitzuweit (Green Bay, Wis.); Stephanie Ronzio (Carlisle, Pa.); and Holly Setson (Smyrna, Ga.).